| Literature DB >> 31243263 |
Zheng Zhou1, Bao Sun2,3, Shiqiong Huang2,3, Lingling Zhao4.
Abstract
Circular RNAs (circRNAs), as a novel class of endogenously expressed non-coding RNAs (ncRNAs), have a high stability and often present tissue-specific expression and evolutionary conservation. Emerging evidence has suggested that circRNAs play an essential role in complex human pathologies. Notably, circRNAs, important gene modulators in the immune system, are strongly associated with the occurrence and development of autoimmune diseases. Here, we focus on the roles of circRNAs in immune cells and immune regulation, highlighting their potential as biomarkers and biological functions in autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), primary biliary cholangitis (PBC), and psoriasis, aiming at providing new insights into the diagnosis and therapy of these diseases.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31243263 PMCID: PMC6594938 DOI: 10.1038/s41419-019-1744-5
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Fig. 1Formation of circRNAs by pre-mRNA back-splicing events.
a The intron complementary repeat sequences or RNA-binding proteins such as QKI, MBL, and NF90/NF110 promote the back-splicing. b A lariat containing one or more skipped exons is re-spliced to generate a circRNA and a double lariat, and the circRNA may be an EIciRNAs or an ecircRNA. c CiRNA is generated from the intron lariat
Association of circRNAs with the development and functions of immune cells
| CircRNAs | Immune cells | Expression state | Functions | References |
|---|---|---|---|---|
| circ-FNDC3B, circ-ELK4, circ-MYBL1 and circ-SLFN12L | Differentiated lymphoid and myeloid cells | Differentially expressed in differentiated lymphoid and myeloid cells | Probably regulated the differentiation and cellular function in hematopoietic cells |
[ |
| 189 differentially expressed circRNAs such as circRNA-010231 | Macrophages | Differentially expressed in the M1 compared with the M2 macrophages | Involved in the differentiation and polarization of macrophages |
[ |
| 1356 new identified circRNAs | Human humoral immune B cells | Differentially expressed in different plasma cells | Exquisitely controlled rearrangement of the Ig during the humoral immune response |
[ |
| mmu_circRNA_007893 | Macrophages | Upregulated in CGRP-stimulated macrophages | Mediated the IL-6 expression by working as an mmu-miR-485-5p sponge |
[ |
| circRNA_100783 | CD8+ T cells | Upregulated in C1 (CD28(+)CD8+ vs CD28(−)CD8+ T cells in the elderly) and C4 (CD28(−)CD8+ T cells in the elderly vs in the adult) cross-comparisons | Possibly regulated phosphoprotein-related signal transduction on CD28-dependent CD8+ T-cell ageing |
[ |
| circANRIL | Macrophages | - | Disrupted pre-rRNA processing and ribosome biogenesis by binding to PES1, which induced apoptosis and inhibited proliferation |
[ |
| circRNAs from TLR6 and MYO1F | Neutrophils | - | Possibly affected the expression of parental immune genes |
[ |
Ig Immunoglobulin, CGRP Calcitonin gene-related peptide, IL-6 Interleukin-6, PES1 Pescadillo homolog 1, TLR6 Toll-like receptor 6, MYO1F Myosin 1F
Fig. 2CircRNAs in immune regulation.
NF90/NF110 enhance back-splicing by stabilizing the intron complementary sequence pairs in the nucleus and are exported to the cytoplasm to suppress viral replication after viral infection. The exogenous circRNA induces innate immune response by activating RIG-I, whereas the endogenous circRNA binds to different RNA-binding proteins that reflect its endogenous biogenesis. hsa_circ_0005105 facilitates the expression of inflammatory cytokines by regulating the miR-26a targeted NAMPT. has_circ_0020397 promotes the expression of PD-L1 by binding to miR-138, thereby participating in tumor immunity. In addition, mcircRasGEF1B induced by LPS is involved in anti-bacteria immunity by modulating the stability of ICAM-1 mRNAs
Fig. 3Roles of circRNAs in autoimmune diseases.
CircRNAs contribute to the development of autoimmune diseases by regulating various biological processes, such as DNA methylation, immune response, and inflammatory response. Furthermore, circRNAs may be used as potential biomarkers for the diagnosis and severity of autoimmune diseases. The overexpression of cia-cGAS can suppress IFN expression in TREX1-deficient BMDMs. The overexpression of dsRNA-containing circRNAs alleviate the aberrant PKR activation cascade in SLE patient-derived cells
Summary of circRNAs involved in autoimmune diseases
| CircRNAs | Disease or model | Cell or tissue type | Functions | References |
|---|---|---|---|---|
| hsa_circ_0045272 | SLE | T cells | Upregulated the early apoptosis of Jurkat cells and enhanced the production of IL-2 in activated Jurkat cells |
[ |
| hsa_circ_0012919 | SLE | CD4+ T cells | Increased DNMT1 expression, reduced CD70 and CD11a expression, rescued the DNA hypomethylation of CD11a and CD70 in CD4+ T cells of SLE patients, as well as regulated the expression of RANTES and KLF13 by bonding to miR-125a-3p |
[ |
| circIBTK | SLE | PBMCs | Inhibited DNA demethylation and activation of AKT signaling pathway by binding to miR-29b |
[ |
| hsa_circ_0049224 and has_circ_0049220 | SLE | PBMCs | Negatively correlated with SLEDAI and the degree of SLE severity |
[ |
| circPTPN22 | SLE | PBMCs | Served as a biomarker for the diagnosis and severity of SLE |
[ |
| hsa_circ_400011, hsa_circ_102584, hsa_circ_101471, and hsa_circ_100226 | SLE | Plasma | Possibly involved in the development of SLE by acting as miRNA sponges |
[ |
| circRNA_002453 | SLE | Plasma | Associated with the renal SLEDAI score and 24-hour proteinuria |
[ |
| hsa_circRNA_407176 and hsa_circRNA_001308 | SLE | Plasma and PBMCs | Served as biomarkers for SLE, and hsa_circRNA_001308 was correlated with CRP and anti-SSA in plasma, as well as leukopenia in PBMCs |
[ |
| hsa_circ_0003090 and hsa_circ_0057762 | SLE | Whole blood | Served as biomarkers for the diagnosis of SLE, and hsa_circ_0057762 was positively associated with the SLEDAI-2K score |
[ |
| ciRS-7 | RA | PBMCs | Reduced the inhibitory effect of miR-7 on mTOR by inhibiting the function of miR-7 |
[ |
| circRNA_104871 | RA | PBMCs | Served as a strong predictor for RA |
[ |
| hsa_circ_0001859 | RA | Synovial tissues | Promoted ATF2 expression and increased inflammatory activity by targeting miR-204/211 |
[ |
| mmu_circRNA_017077 and mmu_circRNA_34132 | RA | Nrf2-knock-out substantia nigra and corpus striatum | Involved in the Nrf2-mediated development of RA by serving as sponges for mmu-miR-346-3p |
[ |
| hsa_circ_0044235 | RA | Peripheral blood | Served as a biomarker for RA and effectively distinguished the patients with RA from those with SLE |
[ |
| An ecircRNA from GSDMB | MS | PBMCs | Involved in the pathogenesis of MS |
[ |
| 49 differentially expressed circRNAs | MS | MALAT1-knockdown Jurkat T cells | Possibly led to the development of MS by affecting splicing and back-splicing events |
[ |
| circ_0005402 and circ_0035560 | MS | Peripheral blood leukocytes | Derived from ANXA2 and served as potential biomarkers for MS |
[ |
| A circRNA chr2:206992521|206994966 | Psoriasis | S-MSCs | Affected the activity of T lymphocytes by regulating the secretion of certain cytokines, including IL-6, IL-11, and hepatocyte growth factor |
[ |
| hsa_circ_0061012, hsa_circ_0003689, chr4:121675708|121732604 and hsa_circ_0003718 | Psoriasis | Psoriatic lesions | Possibly promoted disease progression by interacting with miRNAs associated with psoriasis |
[ |
| hsa_circ_402458 | PBC | Plasma | Possibly acted as a miRNA sponge to moderate inflammation-related signaling pathways |
[ |
| 108 differentially expressed circRNAs | RHD | Atrial tissues | Associated with the development of AF with RHD |
[ |
| cia-cGAS | An autoimmune disease model | TREX1-deficient BMDMs | Suppressed IFN expression in TREX1-deficient BMDMs |
[ |
| dsRNA-containing circRNAs | SLE | PBMCs | Alleviated the aberrant PKR activation cascade in SLE patient-derived cells |
[ |
SLE Systemic lupus erythematosus, RA Rheumatoid arthritis, MS Multiple sclerosis, PBC Primary biliary cholangitis, AF Atrial fibrillation, RHD Rheumatic heart disease, PBMCs Peripheral blood mononuclear cells, Nrf2 Nuclear factor E2-related factor 2, MALAT1 Metastasis associated lung adenocarcinoma transcript 1, S-MSCs Skin mesenchymal stem cells, TREX1 Three-prime repair exonuclease 1, BMDMs Bone marrow derived macrophages, IFN Interferon, IL-2 Interleukin-2, DNMT1 DNA methyltransferase 1, AKT Kinase B, SLEDAI SLE Disease Activity Index, mTOR Mammalian target of rapamycin, CRP C reactive protein, anti-SSA Anti-sjögren’s syndrome-related antigen A, C3 Complement component 3, ATF2 Activating transcription factors 2, miRNA MicroRNA, GSDMB Gasdermin B, ANXA2 Annexin A2, dsRNA Double-stranded RNA, PKR Protein kinase